Publications
Detailed Information
Differential tyrosine phosphorylation of leukemic cells during apoptosis as a result of treatment with imatinib mesylate
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Park, Jungeun | - |
dc.contributor.author | Kim, Sangmi | - |
dc.contributor.author | Oh, Chongkil | - |
dc.contributor.author | Yoon, Sung Soo | - |
dc.contributor.author | Lee, Dongsoon | - |
dc.contributor.author | Kim, Youngsoo | - |
dc.date.accessioned | 2010-01-29T08:06:28Z | - |
dc.date.available | 2010-01-29T08:06:28Z | - |
dc.date.issued | 2005-09-15 | - |
dc.identifier.citation | Biochem Biophys Res Commun. 2005 Oct 28;336(3):942-51. | en |
dc.identifier.issn | 0006-291X (Print) | - |
dc.identifier.uri | http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=16157305 | - |
dc.identifier.uri | http://dx.dor.org/10.1016/j.bbrc.2005.08.201 | - |
dc.identifier.uri | https://hdl.handle.net/10371/47067 | - |
dc.description.abstract | Bcr-Abl fusion tyrosine kinase contributes to leukemic transformation. Imatinib mesylate inhibits Bcr-Abl tyrosine kinase, resulting in a blockage of tyrosine phosphorylation in its downstream pathways. We analyzed the alteration of tyrosine phosphorylation, on BCR/ABL+ chronic myelogenous leukemia cells, after treatment with imatinib mesylate. Data were collected using a two-dimensional gel electrophoresis followed by Western blot and mass spectrometry. The inhibition of Bcr-Abl tyrosine kinase by 2.5 microM imatinib mesylate caused both cell cycle arrest in the G0/G1 phase and increased the portion of apoptotic cells. As a result, the population of leukemic cells decreased by 30% and 70% compared to controls at 24 and 72 h, respectively. Furthermore, treatment with imatinib mesylate altered tyrosine phosphorylation of 24 protein spots as the incubation time proceeded from 0 to 24 and 72 h. Ten of the 24 protein spots are visible at all three times. Four are detectable at both the 0 and 24 h points in time. Eight were detectable only at time 0. | en |
dc.language.iso | en | en |
dc.publisher | Elsevier | en |
dc.subject | Antineoplastic Agents/*pharmacology | en |
dc.subject | Blotting, Western | en |
dc.subject | Cell Cycle/drug effects | en |
dc.subject | Cell Cycle Proteins/genetics/metabolism | en |
dc.subject | Cell Proliferation/drug effects | en |
dc.subject | Electrophoresis, Gel, Two-Dimensional | en |
dc.subject | Fusion Proteins, bcr-abl/*antagonists & inhibitors | en |
dc.subject | Humans | en |
dc.subject | K562 Cells | en |
dc.subject | Leukemia, Myelogenous, Chronic, BCR-ABL | en |
dc.subject | Positive/*enzymology/metabolism/pathology | en |
dc.subject | Phosphorylation | en |
dc.subject | Piperazines/*pharmacology | en |
dc.subject | Protein Kinase Inhibitors/*pharmacology | en |
dc.subject | Proteome/metabolism | en |
dc.subject | Pyrimidines/*pharmacology | en |
dc.subject | Transcription, Genetic/drug effects | en |
dc.subject | Tyrosine/metabolism | en |
dc.subject | Apoptosis | - |
dc.title | Differential tyrosine phosphorylation of leukemic cells during apoptosis as a result of treatment with imatinib mesylate | en |
dc.type | Article | en |
dc.contributor.AlternativeAuthor | 박정은 | - |
dc.contributor.AlternativeAuthor | 김상미 | - |
dc.contributor.AlternativeAuthor | 오종길 | - |
dc.contributor.AlternativeAuthor | 윤성수 | - |
dc.contributor.AlternativeAuthor | 이동순 | - |
dc.contributor.AlternativeAuthor | 김영수 | - |
- Appears in Collections:
- Files in This Item:
- There are no files associated with this item.
Item View & Download Count
Items in S-Space are protected by copyright, with all rights reserved, unless otherwise indicated.